U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO10
Molecular Weight 527.5209
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAUNORUBICIN

SMILES

C[C@@]1([H])[C@]([H])([C@]([H])(C[C@@]([H])(O1)O[C@@]2([H])C[C@@](Cc3c2c(c4c(C(=O)c5cccc(c5C4=O)OC)c3O)O)(C(=O)C)O)N)O

InChI

InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 μg/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
637 μg × h/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.5 h
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DAUNORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 100%)
Thrombocytopenia (grade 4, 16.7%)
Anemia (grade 4, 16.7%)
Sources:
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Disc. AE: Cardiac failure...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 50%)
AEs leading to
discontinuation/dose reduction:
Cardiac failure (grade 5, 16.7%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Disc. AE: Skin toxicity...
AEs leading to
discontinuation/dose reduction:
Skin toxicity (4.2%)
Sources:
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Disc. AE: Skin eruption...
AEs leading to
discontinuation/dose reduction:
Skin eruption (0.9%)
Sources:
80 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
DLT: Acute diverticular perforation...
Dose limiting toxicities:
Acute diverticular perforation
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Disc. AE: Ejection fraction decreased, Prolonged neutropenia...
Other AEs: Granulocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Ejection fraction decreased (5.3%)
Prolonged neutropenia (2.6%)
Other AEs:
Granulocytopenia (grade 4, 21%)
Thrombocytopenia (grade 4, 8%)
Febrile neutropenia (grade 4, 11%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Disc. AE: Infusion related reaction, Myelosuppression...
AEs leading to
discontinuation/dose reduction:
Infusion related reaction (acute)
Myelosuppression (severe)
Cardiotoxicity
Congestive heart failure
Hepatic impairment
Reaction anaphylactic anaphylactoid (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Leucopenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Anemia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Thrombocytopenia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Leucopenia grade 4, 50%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Cardiac failure grade 5, 16.7%
Disc. AE
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Skin toxicity 4.2%
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Skin eruption 0.9%
Disc. AE
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Acute diverticular perforation DLT, Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
Prolonged neutropenia 2.6%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Ejection fraction decreased 5.3%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Febrile neutropenia grade 4, 11%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Granulocytopenia grade 4, 21%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Thrombocytopenia grade 4, 8%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Cardiotoxicity Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Congestive heart failure Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Hepatic impairment Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Infusion related reaction acute
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Reaction anaphylactic anaphylactoid grade 3-5
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Myelosuppression severe
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 203 uM]
yes [Ki 49.4 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Myocardial injury produced by antineoplastic drugs.
1975
Endomyocardial fibrosis associated with daunorubicin therapy.
1976 Aug
Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin.
1976 Jun
Daunorubicin-induced cardiotoxicity.
1976 Mar
Letter: Pericarditis in a case of early daunorubicin cardiomyopathy.
1976 Sep
HIV-1 and HIV-2 reverse transcriptases: a comparative study of sensitivity to inhibition by selected natural products.
1992 May 29
All-trans retinoic acid-induced multiple mononeuropathies.
1999 Apr
IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits.
1999 Mar
Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugs.
1999 Mar
Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors.
1999 Mar-Apr
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
1999 Sep
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
2000
Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
2000 Apr 1
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
2000 Aug 1
Focal degradation of cytoplasmic organelles in cardiomyocytes during regenerative and plastic myocardial insufficiency.
2000 Dec
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
2000 Jul
Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors.
2000 May
Regulation of phospholipase D activity and ceramide production in daunorubicin-induced apoptosis in A-431 cells.
2000 Nov 15
Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
2000 Oct
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
2001 Apr
Ultrastructural changes in cardiomyocyte mitochondria during regenerative and plastic insufficiency of the myocardium.
2001 Feb
Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
2001 Jun
Liposomal encapsulated anthracyclines: new therapeutic horizons.
2001 Mar
Benign thymic hyperplasia after chemotherapy for acute myeloid leukemia.
2001 Oct
Correlation of histopathological and biochemical appraisal of anthracyclin-induced myocardium damage.
2002
Effects of dietary lipids on daunomycin-induced nephropathy in mice: comparison between cod liver oil and soybean oil.
2002 Apr
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
2002 Aug
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits.
2002 Dec
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.
2002 Dec
Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis.
2002 Jun
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
2002 May
Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells.
2002 May
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
2002 May 15
Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
2003
Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury.
2003 Apr
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
2003 Apr
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients.
2003 Dec 1
Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
2003 Feb
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
2003 Jun
Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis.
2003 Jun 15
From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
2003 May-Jun
Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy.
2003 Nov
Neurotoxicity of intrathecal methotrexate: MR imaging findings.
2003 Oct
Population pharmacokinetics of liposomal daunorubicin in children.
2003 Oct
Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity.
2003 Sep 15
Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model.
2004 Jan 1
Patents

Sample Use Guides

Usual Adult Dose for Acute Nonlymphocytic Leukemia: Under 60 years of age: 45 mg/m2 IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Route of Administration: Intravenous
In order to determine the viability of HL-60, K562, THP-1, and HEK293T cells, they were trypsinized, counted, and seeded into 96-well plates and were treated with serial dilutions (0.0001, 0.001, 0.01, 0.1, 1 mkM) of DNR (Daunorubicin). Cell viability was determined 48 h after DNR treatment using the luminescent cell viability assay (Promega) through luminescence testing by BMG NOVOstar machine.
Name Type Language
DAUNORUBICIN
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
FI 6339
Code English
RP 13057
Code English
EPIRUBICIN IMPURITY D
Common Name English
DAUNORUBICIN [MI]
Common Name English
(8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE
Common Name English
DAUNORUBICIN [HSDB]
Common Name English
VYXEOS COMPONENT DAUNORUBICIN
Brand Name English
RP-13057
Code English
5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-
Common Name English
DAUNOMYCIN
Common Name English
VALRUBICIN IMPURITY, DAUNORUBICIN [USP]
Common Name English
FI-6339
Code English
NSC-83142
Code English
EPIRUBICIN HYDROCHLORIDE IMPURITY D [EP]
Common Name English
DAUNORUBICIN [MART.]
Common Name English
EPIRUBICIN HYDROCHLORIDE IMPURITY, DAUNORUBICIN- [USP]
Common Name English
DAUNORUBICIN [WHO-DD]
Common Name English
(1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE IMPURITY A [EP]
Common Name English
DAUNORUBICIN [ORANGE BOOK]
Common Name English
DAUNORUBICIN [VANDF]
Common Name English
DAUNORUBICIN [INN]
Common Name English
DAUNOMYCIN [IARC]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175414
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NCI_THESAURUS C1594
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
FDA ORPHAN DRUG 265808
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ATC L01DB02
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ATC L01XY01
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000000176
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
LIVERTOX 270
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
EU-Orphan Drug EU/3/11/942
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-VATC QL01DB02
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
Code System Code Type Description
HSDB
5095
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
INN
2257
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
EVMPD
SUB06917MIG
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
WIKIPEDIA
DAUNORUBICIN
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL178
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
DRUG BANK
DB00694
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
PUBCHEM
30323
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
EPA CompTox
20830-81-3
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
NCI_THESAURUS
C62091
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
MESH
D003630
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
IUPHAR
7063
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
MERCK INDEX
M4104
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY Merck Index
FDA UNII
ZS7284E0ZP
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
CAS
20830-81-3
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
RXCUI
3109
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
786
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
ECHA (EC/EINECS)
244-069-7
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY